The latest earnings released on Jan 25 definitely disappointed investors and analysts. The expectations were for a $1.94 in earnings. The company was short 4 cents at $1.90. However it was up from last year $1.48 and revenue was higher at $8.3 billion for the quarter versus $7.7 billion last year for the same quarter.
Investors and analysts are not happy with the quarterly results and with news from the company that they expect steeper decline in Humira’s overseas sales.
Here are the trades I have started this morning within the stock.
. This AbbVie Stock (ABBV) article is for FullyInformed Members.
AbbVie Stock (ABBV) – Trade Alert In The Stock Sell-Off – Jan 28 2019
Disclaimer: There are risks involved in all investment strategies and investors can and do lose capital. You trade at your own risk. The author assumes no liability for your investment decisions. Read the full disclaimer.
Internal Stock and Option Trades Links